Tracers / [211At]At-211-MX35
[211At]At-211-MX35
Also written as At-211-MX35
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- Monoclonal antibody (murine MX35, anti-NaPi2b) radiolabeled with astatine-211
- Target / mechanism
- Targets NaPi2b cell surface glycoprotein on ovarian cancer cells PMID 32987283
- Clinical application
- Alpha-radioimmunotherapy of minimal residual ovarian cancer PMID 25970341
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 63 (±7) % | 96 (±3) % | MX35 Ludwig Institute for Cancer Research, Zürich, Switzerland | 32987283 2021 Transl Oncol The antibodies were conjugated with N-succinimidyl 3-(trimethylstannyl)benzoate (m-MeATE) and radiolabeled as previously described — The overall radiochemical yield was 63 (±7) %. |
| Manual synthesis | — | SPE | 74% and 77% | >95% | N-succinimidyl 3-(trimethylstannyl)benzoate (m-MeATE) Toronto Research Chemicals | 25970341 2015 PLoS One Astatination was performed as previously described [18]. Briefly; a 50–100 MBq dry astatine residue was activated by adding N-iodosuccinimide in methanol containing 1% acetic acid. — Radiochemical yields were 42% and 46% for iodination and 74% and 77% for astatination of murine MX35 and Rebmab200, respectively. |
Need this precursor?We can point you to suppliers for [211At]At-211-MX35, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 32987283: 'The murine IgG mAb MX35, directed against the NaPi2b cell surface glycoprotein, was developed at the Memorial Sloan-Kettering Cancer Center'.